SNU-16（人胃癌細(xì)胞）
CBP60502
詢 價(jià)
索取STR
產(chǎn)品描述
產(chǎn)品數(shù)據(jù)庫
| I. General information | |
| Synonyms: | SNU-16 |
| Background: | SNU-16 was line derived in 1987 by J. Park and associates from ascites of a patient with poorly differentiated carcinoma of the stomach. The line was established from cells taken prior to chemotherapy. |
| Species: | Homo sapiens, human |
| Tissue: | stomach; derived from metastatic site: ascites |
| Disease: | gastric carcinoma |
| Gender: | Asian,female, 33 years |
| Morphology: | epithelial |
| Growth Mode: | suspension, multicell aggregates |
| Doubling Time: | 27 hrs |
| DNA Profile: | Amelogenin: X CSF1PO: 12 D13S317: 8,12 D16S539: 11,13 D5S818: 10,13 D7S820: 12 THO1: 6,9 TPOX: 11 vWA: 16 Our Cell Line Authentication Service |
| Culture Medium: |
RPMI1640+10%FBS SNU-16完全培養(yǎng)基，# CBP60502M |
| Cryopreservation medium: | 90%FBS+10%DMSO |
| Antigen Expression: | Blood Type A; Rh + ,The cells express the surface glycoproteins carcinoembryonic antigen (CEA) and TAG 72. |
| Receptor Expression: | vasoactive intestinal peptide (VIP), expressed , Ref |
| Oncogene: | myc +; erb B2 + |
| Genes Expressed: | myc +; erb B2 +,Blood Type A; Rh +,The cells express the surface glycoproteins carcinoembryonic antigen (CEA) and TAG 72. |
| Tumor Formation: | Yes, the cells have a reported colony forming efficiency of 10% in semisolid medium. |
| Comments: | SNU-16 cells were positive for VIP receptors but lacked gastrin receptors. The line was established from cells taken prior to chemotherapy. No evidence of amplification or rearrangements was noted in the N-myc, L-myc, myb and EGF receptor genes. The c-myc proto-oncogene was apmplified, but expressed c-erb-B-2 RNA that were comparable to other cell lines. There was no expression of the following genes: N-myc, L-myc, c-cis, IGF-2, or gastrin releasing peptide.The cells express the surface glycoproteins carcinoembryonic antigen (CEA) and TAG-72. The cells are L-dopa decarboxylase (DDC) positive. For more information, please contact us (4008-750-250). |
